TY - JOUR
T1 - ORY-1001
T2 - Overcoming the Differentiation Block in AML
AU - Bose, Prithviraj
AU - Konopleva, Marina Y.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/3/12
Y1 - 2018/3/12
N2 - In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001—an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)—in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001. In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001—an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)—in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
AB - In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001—an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)—in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001. In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001—an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)—in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
UR - http://www.scopus.com/inward/record.url?scp=85042639009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042639009&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2018.02.014
DO - 10.1016/j.ccell.2018.02.014
M3 - Short survey
C2 - 29533778
AN - SCOPUS:85042639009
SN - 1535-6108
VL - 33
SP - 342
EP - 343
JO - Cancer Cell
JF - Cancer Cell
IS - 3
ER -
